Roivant Sciences Ltd.
ROIV
$27.85
-$0.25-0.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | 1.57M | 2.17M | 7.57M | 9.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | 1.57M | 2.17M | 7.57M | 9.02M |
| Cost of Revenue | 166.08M | 164.18M | 152.57M | 145.04M | 140.15M |
| Gross Profit | -164.08M | -162.61M | -150.40M | -137.47M | -131.14M |
| SG&A Expenses | 175.05M | 129.53M | 128.22M | 227.69M | 132.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 341.13M | 293.70M | 280.79M | 372.74M | 272.50M |
| Operating Income | -339.14M | -292.13M | -278.62M | -365.17M | -263.48M |
| Income Before Tax | -290.37M | -159.04M | -269.26M | -203.05M | -234.51M |
| Income Tax Expenses | 23.33M | 7.00M | 4.65M | 49.32M | -25.57M |
| Earnings from Continuing Operations | -313.70M | -166.04M | -273.91M | -252.38M | -208.95M |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00 | 327.02M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 47.81M | 52.52M | 50.56M | 45.90M | 51.31M |
| Net Income | -265.89M | -113.52M | -223.36M | -206.48M | 169.38M |
| EBIT | -339.14M | -292.13M | -278.62M | -365.17M | -263.48M |
| EBITDA | -338.44M | -291.21M | -277.52M | -357.00M | -261.54M |
| EPS Basic | -0.38 | -0.17 | -0.33 | -0.29 | 0.23 |
| Normalized Basic EPS | -0.21 | -0.17 | -0.15 | -0.20 | -0.10 |
| EPS Diluted | -0.38 | -0.17 | -0.33 | -0.29 | 0.23 |
| Normalized Diluted EPS | -0.21 | -0.17 | -0.15 | -0.20 | -0.10 |
| Average Basic Shares Outstanding | 696.86M | 680.95M | 680.29M | 707.30M | 722.72M |
| Average Diluted Shares Outstanding | 696.86M | 680.95M | 680.29M | 707.30M | 722.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |